CABA
MaterialsCabaletta Bio Inc
Live · NASDAQ · May 9, Close
What's Moving CABA Today?
No stock-specific AI insight has been generated for CABA yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
CABA News
20 articles- Cabaletta Bio Announces Pricing of $150 Million Underwritten OfferingYahoo Finance·May 4, 2026
- Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-celYahoo Finance·Apr 28, 2026
- Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-celYahoo Finance·Apr 28, 2026
- Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual MeetingYahoo Finance·Apr 27, 2026
- First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ PlatformYahoo Finance·Apr 14, 2026
- This Biotech Stock Could Deliver 350% Returns in 12 MonthsYahoo Finance·Mar 27, 2026
- Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 23, 2026
- Cabaletta Bio Highlights Pivotal Myositis Trial, No-Preconditioning CAR-T Push at TD Cowen ConferenceMarketbeat·Mar 7, 2026
- Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Mar 6, 2026
- Are Medical Stocks Lagging Biodesix (BDSX) This Year?Yahoo Finance·Mar 3, 2026
- Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 24, 2026
- Here’s Why Jacob Funds Established a Position in Cabaletta Bio (CABA)Yahoo Finance·Feb 18, 2026
- Cabaletta Bio Kicks Off Pivotal Myositis Trial, Touts Automated CAR-T Manufacturing Path to 2027 BLAMarketbeat·Feb 13, 2026
- Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Feb 12, 2026
- Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 5, 2026
- What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now?Yahoo Finance·Jan 30, 2026
- Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year?Yahoo Finance·Jan 27, 2026
- Assessing Cabaletta Bio (CABA) Valuation After Insider Buying And FDA Clearance For Automated CAR T ManufacturingYahoo Finance·Jan 26, 2026
- Why Cabaletta Bio (CABA) Is Up 41.3% After FDA Clears Automated CAR T Manufacturing PlatformsYahoo Finance·Jan 23, 2026
- Cabaletta Bio Announces 2026 Strategic PrioritiesYahoo Finance·Jan 12, 2026
All 20 articles loaded
Price Data
Fundamentals
Trading
About Cabaletta Bio Inc
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.